2022-02-18
NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy
On February 23rd at 10.40 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye.
The presentation is live broadcasted and can be followed at https://www.redeye.se/events/825130/redeye-theme-regenerative-medicine-cell-therapy where the replay and the presentations will be available afterwards.
On February 23rd at 10.40 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye.
The presentation is live broadcasted and can be followed at https://www.redeye.se/events/825130/redeye-theme-regenerative-medici...
Read moreRead more2022-02-08
NextCell invests in CAR-T technology
NextCell Pharma AB ("NextCell" or the"Company") informs that FamiCordTx, a joint venture cell-gene biopharma company issues new share. The major shareholders, PBKM and NextCell will participate at 50% of their pro rata rights. For NextCell this results in an investment of approximately kEUR 160, whereas its ownership in FamiCordTx will change from 9,43% to 8,45% of the then shares.
FamiCordTx S.A., raised PLN 16 million (approximatly MEUR 3,5) from a pre-IPO issue of shares
• The proceeds from the issue will be used to fund the Phase 1 clinical trials of CAR T (chimeric antigen receptor
NextCell Pharma AB ("NextCell" or the"Company") informs that FamiCordTx, a joint venture cell-gene biopharma company issues new share. The major shareholders, PBKM and NextCell will participate at 50% of their pro rata rights. For NextCell this results in an investment of approximately kEUR 160, ...
Read moreRead more2022-01-27
NextCell Pharma publishes Interim Report 1 2021/2022
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2021 - November 30, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report
NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
First quarter (2021-09-01 until 2021-11-30)
● Operating income amounted to TSEK 1 347 (1 148).
● Operating result amounted to TSEK -6 472 (-5 473).
● Earnings per share* amounted to
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2021 - November 30, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report
NextCells share is traded on Nasdaq First North Growth ...
Read moreRead more2022-01-25
NextCell invited speaker at the prestigious Advanced Therapy Week in USA
NextCell Pharma AB ("NextCell" or the"Company") has been invited to give a presentation about the company journey within the cell therapy arena. Starting as a Karolinska Institute spin-out to phase II clinical trials listed on Nasdaq.
The Miami-based meeting is the largest event in the Cell & Gene Therapy arena and brings together a range of key opinion leaders in the advanced therapies field with an expected 1650 participants. The wider theme for the meeting is to advocate for the application of advanced therapies in healthcare, by innovation & investment, manufacturing, logistics and
NextCell Pharma AB ("NextCell" or the"Company") has been invited to give a presentation about the company journey within the cell therapy arena. Starting as a Karolinska Institute spin-out to phase II clinical trials listed on Nasdaq.
The Miami-based meeting is the largest event in the Cell & Ge...
Read moreRead more2021-12-13
NextCell collaborates with T.A.D.1 and T1D app
NextCell Pharma AB ("NextCell" or the"Company") has entered into a collaboration agreement with T.A.D.1, a non-profit association whose purpose is to increase knowledge in society about type 1 diabetes and run projects to support everyone living with and around T1D. Together, we want to spread hope for type 1 diabetes and make NextCell's clinical trials visible.
Every year, more than 900 children are diagnosed with type 1 diabetes and at least as many are diagnosed in adulthood. The disease has a huge impact on life and something that needs to be dealt with daily, for the rest of your life.
NextCell Pharma AB ("NextCell" or the"Company") has entered into a collaboration agreement with T.A.D.1, a non-profit association whose purpose is to increase knowledge in society about type 1 diabetes and run projects to support everyone living with and around T1D. Together, we want to spread h...
Read moreRead more2021-10-29
NextCell publishes its Year-End Report 2020/2021
NextCell Pharma AB (publ) (NXTCL) publishes its Year-End Report for the period September 1, 2020 - August 31, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report
NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.
Fourth quarter (2021-06-01 until 2021-08-31)
● Operating income amounted to TSEK 1 381 (842).
● Operating result amounted to TSEK -4 475 (-4 877).
● Earnings per share* amounted to SEK -0,13 (-0,22).
NextCell Pharma AB (publ) (NXTCL) publishes its Year-End Report for the period September 1, 2020 - August 31, 2021 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report
NextCells share is traded on Nasdaq First North Growth Market under th...
Read moreRead more2021-10-26
NextCell to begin treatment with medium dose in COVID-19
NextCell Pharma AB ("NextCell" or the "Company") announces that the clinical trial ProTrans19+SE can commence to enroll patients in the medium dose group. Three patients having received a low dose ProTrans, have been clinically assessed and evaluated by the Data and Safety Monitoring Board, which now allows continuation with medium dose treatment of ProTrans for COVID-19 induced servere pneumonia.
The Data and Safety Monitoring Board (DSMB) has reviewed safety aspects of the study "Treatment of Respiratory Complications Associated with COVID-19 Infection Using Wharton's Jelly (WJ) Umbilical
NextCell Pharma AB ("NextCell" or the "Company") announces that the clinical trial ProTrans19+SE can commence to enroll patients in the medium dose group. Three patients having received a low dose ProTrans, have been clinically assessed and evaluated by the Data and Safety Monitoring Board, which...
Read moreRead more2021-10-26
NextCell increases market potential and reduces the risk of ProTrans' clinical trial program in type 1 diabetes
NextCell Pharma AB ("NextCell" or the "Company") updates the strategy for the clinical trial program in type 1 diabetes with ProTrans. The aim is to increase potential while reducing the risk. This can be achieved by waiting for preliminary safetydata from the approved ProTrans-Young pediatric trial before submitting the application for ProTrans-3, scheduled for H2 2022.
Advantages of the updated strategy for future application for marketing approval are:
· Lower age limit for treatment is desirable and could potentially double the intitial market
· Increased long term data from
NextCell Pharma AB ("NextCell" or the "Company") updates the strategy for the clinical trial program in type 1 diabetes with ProTrans. The aim is to increase potential while reducing the risk. This can be achieved by waiting for preliminary safetydata from the approved ProTrans-Young pediatric tr...
Read moreRead more